Drug intelligence / Profile preview

LTG-002

Development stage: Unknown
Lead developer: Latigo Biotherapeutics
Modality: Small Molecules
Administration: Oral

Overview

LTG-002 is an orally available small molecule inhibitor of the voltage-gated sodium channel Nav1.8 (SCN10A), currently in Phase 1 clinical development by Latigo Biotherapeutics for the treatment of pain. Nav1.8 is a sodium channel subtype selectively expressed in peripheral nociceptors, where it plays a key role in the initiation and propagation of action potentials in response to painful stimuli. By specifically targeting Nav1.8, LTG-002 is designed to provide potent pain relief without the central nervous system side effects or addiction potential associated with opioids and non-selective sodium channel blockers.

Other names: Nav1.8 Program 2Nav-1.8 Program 2Nav 1.8 Program 2

Targets

SCN10A (Sodium channel protein type X alpha subunit)

Beyond the preview

Go deeper on LTG-002.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LTG-002.

Explore the full profile